The importance of efficacy studies performed in large animal models of pain.
One of the challenges in the life sciences industry is improving the approval rate of neurology and pain treatments. While our understanding of neurology is growing, there are still several limitations. Compared to other therapeutic areas, there are fewer predictive models, fewer known biomarkers that help quantify disease, and a narrow scope of human data. Consequently, the development of neurological treatments heavily depends on qualitative and subjective measures, which is an inadequate predictor of disease and treatment. MD Biosciences is combatting this challenge by developing translational models and novel quantitative measures that help de-risk clinical trials.